Acciones Immunoprecise Antibodies Ltd Other OTC
Acciones
CA87588T1030
Farmacéuticos
Ventas 2024 * | 24,59 M 17,95 M 16,81 M | Ventas 2025 * | 29,82 M 21,77 M 20,38 M | Capitalización | 35,94 M 26,24 M 24,56 M |
---|---|---|---|---|---|
Resultado Neto 2024 * | -12 M -8,76 M -8,2 M | Resultado Neto 2025 * | -9 M -6,57 M -6,15 M | VE / Ventas 2024 * | 1,46 x |
Posición de caja neta 2024 * | - 0 0 | Posición de caja neta 2025 * | - 0 0 | VE / Ventas 2025 * | 1,21 x |
P/E ratio 2024 * |
-2,85
x | P/E ratio 2025 * |
-3,86
x | Empleados | - |
Rendimiento 2024 * |
-
| Rendimiento 2025 * |
-
| Flotante | 86,41 % |
Último transcript sobre Immunoprecise Antibodies Ltd
Directores | Puesto | Edad | Desde |
---|---|---|---|
Jennifer Bath
CEO | Chief Executive Officer | - | 21/02/18 |
Kristin Taylor
DFI | Director of Finance/CFO | - | 29/09/23 |
Ilse Roodink
CTO | Chief Tech/Sci/R&D Officer | - | 01/07/21 |
Administradores | Puesto | Edad | Desde |
---|---|---|---|
Mitchell Levine
CHM | Chairman | - | - |
Chris Buyse
BRD | Director/Board Member | 59 | 05/09/23 |
Jennifer Bath
CEO | Chief Executive Officer | - | 21/02/18 |
Varia. 1 de ene. | Capi. | |
---|---|---|
+2,87 % | 94,22 mil M | |
-4,08 % | 37,76 mil M | |
-13,45 % | 32,5 mil M | |
+73,38 % | 27,75 mil M | |
-11,58 % | 16,13 mil M | |
-0,35 % | 14,19 mil M | |
-11,67 % | 11,42 mil M | |
+190,36 % | 11,06 mil M | |
-52,61 % | 9088,09 M |